NCT06963203 Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
| NCT ID | NCT06963203 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Andrea Goldmann |
| Condition | Graves Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 486 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 486 participants in total. It began in 2025-07-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the potential differences in morbidity of thyroidectomy (removal of the thyroid gland) depending on the preoperative hormonal status. The main question it aims to answer is: Do patients undergoing thyroidectomy for thyreotoxicosis (thyroid hyperfunction) due to Graves' disease or Amiodarone induced thyreotoxicosis have comparable complication rates depending on their thyroid metabolic status prior or during the procedure. The data from participants undergoing a thyroidectomy at one of the study sites will be prospectively registered in the EUROCRINE registry, including an add-on module for additional study specific routine data. The operation itself, the preoperative or postoperative treatments are not altered in any way.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years of age) undergoing surgical treatment for Graves' disease or Amiodarone-induced thyrotoxicosis (AIT) with biochemically confirmed hyperthyroidism or on specific medication for the treatment of Graves' disease or AIT. * Patients providing signed informed consent. Exclusion Criteria: * Children and minors (\<18 years). * Pregnant women. * Patients unable or unwilling to provide informed consent due to language barriers or intellectual limitations. * Patients undergoing concurrent parathyroidectomy for primary or secondary hyperparathyroidism, lymph node clearance, or redo surgery. * Surgical procedures performed for other reasons than Graves' disease or AIT
Contact & Investigator
Andrea Goldmann, MD
PRINCIPAL INVESTIGATOR
Kantonsspital Winterthur KSW
Frequently Asked Questions
Who can join the NCT06963203 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Graves Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06963203 currently recruiting?
Yes, NCT06963203 is actively recruiting participants. Contact the research team at andrea.goldmann@ksw.ch for enrollment information.
Where is the NCT06963203 trial being conducted?
This trial is being conducted at Aalst, Belgium, Nancy, France, Athens, Greece, Granada, Spain and 11 additional locations.
Who is sponsoring the NCT06963203 clinical trial?
NCT06963203 is sponsored by Andrea Goldmann. The principal investigator is Andrea Goldmann, MD at Kantonsspital Winterthur KSW. The trial plans to enroll 486 participants.